{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:25:48Z","timestamp":1779935148789,"version":"3.53.1"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T00:00:00Z","timestamp":1355184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology Research"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The historical standard of care for patients with chronic hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) was peginterferon (<jats:styled-content style=\"fixed-case\">PEG IFN<\/jats:styled-content>) and ribavirin combination therapy, yielding sustained virological response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) rates of 38\u201352% in <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1 patients. This study evaluated a novel three\u2010drug regimen of nitazoxanide and high\u2010dose ribavirin as lead\u2010in therapy, followed by <jats:styled-content style=\"fixed-case\">PEG IFN<\/jats:styled-content>\u2010\u03b1\u20102a in triple therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective, open\u2010label pilot study was conducted in treatment\u2010naive patients with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1. Patients received nitazoxanide 500\u2009mg twice a day for 2 weeks, then nitazoxanide plus ribavirin 1400\u2009mg\/day for 2 weeks, then nitazoxanide plus ribavirin plus <jats:styled-content style=\"fixed-case\">PEG IFN<\/jats:styled-content>\u2010\u03b1\u20102a 180\u2009\u03bcg weekly for 12 weeks, followed by ribavirin plus <jats:styled-content style=\"fixed-case\">PEG IFN<\/jats:styled-content>\u2010\u03b1\u20102a for 12 weeks (48 weeks if <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> negative after week 24). Primary outcome was <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>. Other outcomes included very rapid virological response (<jats:styled-content style=\"fixed-case\">VRVR<\/jats:styled-content>), rapid virological response (<jats:styled-content style=\"fixed-case\">RVR<\/jats:styled-content>), early virological response (<jats:styled-content style=\"fixed-case\">EVR<\/jats:styled-content>), end\u2010of\u2010treatment response (<jats:styled-content style=\"fixed-case\">ETR<\/jats:styled-content>), and safety and tolerability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010three patients with a mean age of 46 years, detectable <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> (64% with &lt;600\u2009000\u2009<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/m<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>), and METAVIR fibrosis scores (<jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>1:<jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>2:<jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>3) of 15%:49%:36% were enrolled. Outcomes were as follows: <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>, 67% (22\/33); <jats:styled-content style=\"fixed-case\">VRVR<\/jats:styled-content>, 39% (13\/33); <jats:styled-content style=\"fixed-case\">RVR<\/jats:styled-content>, 48% (16\/33); <jats:styled-content style=\"fixed-case\">EVR<\/jats:styled-content>, 70% (23\/33); and <jats:styled-content style=\"fixed-case\">ETR<\/jats:styled-content>, 67% (22\/33). Most patients required at least one growth factor. Two patients discontinued because of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This three\u2010drug regimen was effective in achieving <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> in patients with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1. No patients relapsed, and the toxicity profile was favorable. Further studies on the role of nitazoxanide in the treatment of chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hepr.12013","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T21:56:52Z","timestamp":1354744612000},"page":"589-595","source":"Crossref","is-referenced-by-count":2,"title":["Effects of triple\u2010drug therapy with nitazoxanide, high\u2010dose ribavirin and peginterferon\u2010\u03b1\u20102a in patients with chronic hepatitis <scp>C<\/scp>"],"prefix":"10.1111","volume":"43","author":[{"given":"P. Patrick","family":"Basu","sequence":"first","affiliation":[{"name":"Division of Digestive and Liver Diseases and Center for Liver Disease and Transplantation Columbia University Medical Center  New York NY USA"},{"name":"North Shore University Hospital at Forest Hills  Forest Hills NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Rayapudi","sequence":"additional","affiliation":[{"name":"North Shore University Hospital at Forest Hills  Forest Hills NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niraj James","family":"Shah","sequence":"additional","affiliation":[{"name":"North Shore University Hospital at Forest Hills  Forest Hills NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Krishnaswamy","sequence":"additional","affiliation":[{"name":"North Shore University Hospital at Forest Hills  Forest Hills NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases and Center for Liver Disease and Transplantation Columbia University Medical Center  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2005.05.003"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.014"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36791"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct061675"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9041265"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/82191"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C100349200"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04082"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20563"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.01.017"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.08.005"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.07.056"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.11.037"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21712"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.05.067"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-08"},{"key":"e_1_2_6_23_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/MCG.0b013e3181bf9b15","article-title":"Treatment of chronic hepatitis C using a 4\u2010week lead\u2010in with nitazoxanide before peginterferon plus nitazoxanide","volume":"44","author":"Rossignol JF","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06550.x"},{"key":"e_1_2_6_25_1","volume-title":"(telaprevir) Prescribing Information","author":"INCIVEK","year":"2011"},{"key":"e_1_2_6_26_1","volume-title":"(boceprevir) Prescribing Information","author":"VICTRELIS","year":"2011"},{"issue":"1","key":"e_1_2_6_27_1","first-page":"356A","article-title":"Potential role for nitazoxanide in combination with STAT\u2010C agents for the inhibition of HCV replication without the development of resistance [AASLD abstract 115]","volume":"48","author":"Korba B","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_28_1","first-page":"546A","article-title":"Nitazoxanide exhibits synergy with HCV protease inhibitors and prevents the emergence of telaprevir\u2010resistant HCV mutants in combination treatments in cell culture [AASLD abstract 377]","volume":"54","author":"Korba B","year":"2011","journal-title":"Hepatology"}],"container-title":["Hepatology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhepr.12013","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hepr.12013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:05:21Z","timestamp":1697353521000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hepr.12013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/hepr.12013"],"URL":"https:\/\/doi.org\/10.1111\/hepr.12013","archive":["Portico"],"relation":{},"ISSN":["1386-6346","1872-034X"],"issn-type":[{"value":"1386-6346","type":"print"},{"value":"1872-034X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,11]]}}}